Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Belatacept

Nature Reviews Drug Discovery volume 10, pages 655–656 (2011)Cite this article

Subjects

Abstract

In June 2011, belatacept (Nulojix; Bristol-Myers Squibb), a fusion protein that inhibits T cell activation by binding to CD80 and CD86, was approved by the US Food and Drug Administration (FDA) for the prophylaxis of organ rejection in adult patients receiving a kidney transplant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Webber, A., Hirose, R. & Vincenti, F. Novel strategies in immunosuppression: issues in perspective. Transplantation 91, 1057–1064 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Lamb, K. E., Lodhi, S. & Meier-Kriesche, H.-U. Long-term renal allograft survival in the United States: a critical reappraisal. Am. J. Transplant. 11, 450–462 (2011).

    Article  CAS  PubMed  Google Scholar 

  3. Linsley, P. S. et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792–795 (1992).

    Article  CAS  PubMed  Google Scholar 

  4. Larsen, C. P. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443–453 (2005).

    Article  CAS  PubMed  Google Scholar 

  5. US Food and Drug Administration. FDA labeling information — Nulojix. FDA website [online], (2011).

  6. Vincenti, F. et al. A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10, 535–546 (2010).

    Article  CAS  PubMed  Google Scholar 

  7. Durrbach, A. et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10, 547–557 (2010).

    Article  CAS  PubMed  Google Scholar 

  8. Gaston, R. S. et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 290, 68–74 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Flavio Vincenti is at the University of California, San Francisco, 505 Parnassus Ave, Moffitt 884 San Francisco, California 94143-0780, USA. Flavio.Vincenti@ucsfmedctr.org,

    Flavio Vincenti

  2. Argyris Dritselis is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. ADritselis@imscg.com,

    Argyris Dritselis

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Flavio Vincenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Argyris Dritselis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Flavio Vincenti has received a research grant from Bristol-Myers Squibb.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vincenti, F., Dritselis, A. & Kirkpatrick, P. Belatacept. Nat Rev Drug Discov 10, 655–656 (2011). https://doi.org/10.1038/nrd3536

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3536

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research